The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris

The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also sig...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Wiederhold, Nathan P., Najvar, Laura K., Jaramillo, Rosie, Olivo, Marcos, Patterson, Hoja, Connell, April, Fukuda, Yoshiko, Mitsuyama, Junichi, Catano, Gabriel, Patterson, Thomas F.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2020
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038306/
https://ncbi.nlm.nih.gov/pubmed/31844006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02198-19
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires